INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 177 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2020. The put-call ratio across all filers is 0.76 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $389,000 | -21.9% | 8,357 | -4.1% | 0.15% | -39.4% |
| Q2 2022 | $498,000 | +78.5% | 8,716 | -19.9% | 0.25% | -64.4% |
| Q3 2020 | $279,000 | +27.4% | 10,882 | +7.6% | 0.70% | +636.8% |
| Q3 2018 | $219,000 | -58.9% | 10,109 | -66.5% | 0.10% | -43.8% |
| Q2 2018 | $533,000 | +38.1% | 30,162 | +13.3% | 0.17% | +49.6% |
| Q4 2017 | $386,000 | -1.0% | 26,625 | +7.8% | 0.11% | +2.7% |
| Q3 2017 | $390,000 | +68.8% | 24,700 | +61.4% | 0.11% | -9.1% |
| Q4 2016 | $231,000 | -27.4% | 15,300 | +86.6% | 0.12% | -21.4% |
| Q2 2016 | $318,000 | – | 8,200 | – | 0.15% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 424,500 | $13,499,000 | 5.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 200,000 | $6,360,000 | 3.70% |
| Asymmetry Capital Management, L.P. | 130,654 | $4,155,000 | 1.90% |
| Altium Capital Management LP | 153,348 | $4,876,000 | 1.82% |
| Sofinnova Investments, Inc. | 848,162 | $26,972,000 | 1.61% |
| Bellevue Group AG | 3,659,919 | $116,386,000 | 1.33% |
| Eversept Partners, LP | 356,235 | $11,328,273 | 1.33% |
| Rhenman & Partners Asset Management AB | 500,000 | $15,900,000 | 1.30% |
| GENERAL AMERICAN INVESTORS CO INC | 347,497 | $11,050,000 | 1.09% |
| WASATCH ADVISORS LP | 6,333,900 | $201,418,000 | 0.99% |